ketorolac and Recrudescence

ketorolac has been researched along with Recrudescence in 9 studies

Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.

Research

Studies (9)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Overall Survival

2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of death from any cause assessed up to 5 years) (NCT01806259)
Timeframe: 5 years

Recurrence-free Survival

2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years) (NCT01806259)
Timeframe: 5 years

Change in Pain Score

At baseline at at 60 minutes, all patients were asked to describe their pain on a scale from 0 to 10, with 0 representing no pain and 10 the worst imaginable. The primary outcome is the 60 minute score subtracted from the baseline score (NCT01011673)
Timeframe: Baseline, 60 minutes

Satisfaction Scores

"24 hours after the emergency department visit, patients were asked, The next time you come to the Er with this type of headache, do you want to receive the same medication? Affirmative answers are tabulated here." (NCT01011673)
Timeframe: 24 hours

Anxiety

Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes

Headache Following Intervention

Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes

Nausea

Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes

The Number of Participants Experiencing Vomiting

Yes/No (NCT02657031)
Timeframe: 0-60 minutes

The Number of Patients Experiencing Restlessness

Yes/No (NCT02657031)
Timeframe: 0-60 minutes

Reviews

1 review available for ketorolac and Recrudescence

Trials

2 trials available for ketorolac and Recrudescence

Other Studies

6 other studies available for ketorolac and Recrudescence